Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ryuto Tomabechi"'
Autor:
Ryuto Tomabechi, Miki Miyasato, Taeka Sato, Tappei Takada, Kei Higuchi, Hisanao Kishimoto, Yoshiyuki Shirasaka, Katsuhisa Inoue
Publikováno v:
Molecular pharmaceutics. 20(1)
The therapeutic modalities that involve the endocytosis pathway, including antibody-drug conjugates (ADCs), have recently been developed. Since the drug escape from endosomes/lysosomes is a determinant of their efficacy, it is important to optimize t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b92bd5f4f77d51d4ec5a75590575fe
https://pubmed.ncbi.nlm.nih.gov/36458938
https://pubmed.ncbi.nlm.nih.gov/36458938
Autor:
Ryuto Tomabechi, Hisanao Kishimoto, Taeka Sato, Naoki Saito, Keisuke Kiyomiya, Tappei Takada, Kei Higuchi, Yoshiyuki Shirasaka, Katsuhisa Inoue
Publikováno v:
PNAS Nexus. 1
Antibody–drug conjugates (ADCs) represent a new class of cancer therapeutics that enable targeted delivery of cytotoxic drugs to cancer cells. Although clinical efficacy has been demonstrated for ADC therapies, resistance to these conjugates may oc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::133063f103fd940bbac271bf520d48f0
https://doi.org/10.1093/pnasnexus/pgac063
https://doi.org/10.1093/pnasnexus/pgac063
Publikováno v:
Journal of Biological Chemistry. 298:101800
Monocarboxylate transporter 7 (MCT7) is an orphan transporter expressed in the liver, brain, and in several types of cancer cells. It has also been reported to be a survival factor in melanoma and breast cancers. However, this survival mechanism is n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d555105dbf6f2c100f6948e7134e5a
https://doi.org/10.1016/j.jbc.2022.101800
https://doi.org/10.1016/j.jbc.2022.101800